Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Nov 26;8(12):70. doi: 10.1038/s41389-019-0179-2

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2019

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 1 — a, b Analysis of the relationship between the high expression of EGFR (the mRNA expression of EGFR exceeds the average value of the test samples) and disease-free survival in cervical cancer patients (TCGA, n = 264) (a) and cervical cancer patients with chemotherapy (TCGA, n = 65) (b). c Western blot analysis was performed to detect the protein levels of phosphorylation of EGFR (pEGFR) and EGFR in HeLa229P and HeLa229/TR cells after treated with 0 μM or 5 μM erlotinib for 48 h. d Sphere-formation assay, flow cytometry assay of CD133, and colony-forming assay were performed in HeLa229P and HeLa229/TR cells with or without 5 μM erlotinib treatment for 48 h. e The protein levels of pEGFR and EGFR in SiHaP and SiHa/TR cells with or without 5 μM erlotinib treatment for 48 h were measured by western blot. f The spheres number, the percentage of CD133⁺ cells, and the colonies number in SiHaP and SiHa/TR cells with or without 5 μM erlotinib treatment for 48 h were detected. Data represent mean ± SD from three independent experiments (n = 3). Differences between linked groups were evaluated by two-tailed Student’s t test. ***P < 0.001; ns not significant, P parental, TR paclitaxel-resistant, Erl erlotinib.